Development programme
TRIUMPH — retatrutide
The phase 3 programme for the triple GIP, GLP-1 and glucagon receptor agonist retatrutide. At the assessment date the programme had not reported a completed phase 3 result, and the Institute grades retatrutide outcomes on phase 2 evidence only.
The phase 3 programme for the triple GIP, GLP-1 and glucagon receptor agonist retatrutide. At the assessment date the programme had not reported a completed phase 3 result, and the Institute grades retatrutide outcomes on phase 2 evidence only.
Sponsor class: Manufacturer-sponsored. First record: 2022.
Showing 0 records on this page
Records in this programme
17 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| TRIUMPH-1 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-2 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-3 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-4 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-OSA | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-1-DDIprogramme record | Retatrutide | Phase 1 | Ongoing | Randomised crossover | — | — | Very low |
| TRIUMPH-1-PKprogramme record | Retatrutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| TRIUMPH-1-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| TRIUMPH-2-BODY-COMPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-2-QOLprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-2-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-2-REGIONAL-JPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-3-BIOMARKERprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-3-OLEprogramme record | Retatrutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |
| TRIUMPH-4-BODY-COMPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-4-REGIONAL-JPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-OSA-OLEprogramme record | Retatrutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |